IBI308
IBI308 is a pharmaceutical drug with 8 clinical trials. Currently 1 active trials ongoing. Historical success rate of 80.0%.
Success Metrics
Based on 4 completed trials
Phase Distribution
Phase Distribution
2
Early Stage
4
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
80.0%
4 of 5 finished
20.0%
1 ended early
1
trials recruiting
8
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC
The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery
A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC
First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors
IBI308 in Subjects With Advanced/Metastatic Solid Malignancies
Clinical Trials (8)
Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC
The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery
A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC
First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors
IBI308 in Subjects With Advanced/Metastatic Solid Malignancies
Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment
Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy
CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients
All 8 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 8